Liposomes are versatile and well-proven as a means to deliver nucleic acids into cells. Most of the formulation procedures used are labour intensive and result in unstable end products.
INTRODUCTION
Various methods for formulating polynucleotide-loaded PEGylated particles have been reported to date, including post-insertion 1 , reverse-phase evaporation 2 , detergent dialysis 3 and ethanol dialysis [4] [5] [6] . However, most of these methods, though effective, require relatively complicated and lengthy formulation procedures with the resulting particles suspended in an aqueous state. This has led to long term storage issues including aggregation and/or fusion of the particles 7, 8 , hydrolysis of the lipids 7 , and instability of siRNA nucleotides in an aqueous environment. Moreover, these formulations are also prone to be affected by stresses occurred during transport, such as agitation or temperature fluctuation 8, 9 . These problems, along with the significantly increased effort required for large-scale production of these particles using the existing formulation procedures has held back clinical development and adoption.
To address these issues, we developed a novel method to formulate stable, siRNA-loaded, PEGylated lipid particles using the hydration of freeze-dried matrix (HFDM) method 10 . This simple, yet-efficient, procedure results in lipid particles that are have highly favourable characteristics for in vivo delivery. Indeed, these particles have been used for in vivo systemic delivery in animal models to target a range of cancer-related genes, which have resulted in significant tumour elimination and increased survival 11, 12 . HDFM lipoplexes have also been used to reduce gene expression in lung tissues 13 , the peritoneal cavity via intraperitoneal delivery 14 and in the vaginal epithelia with the aid of a novel aliginate matrix to increase retention time 15 .
The simple mixing of lipids (DOTAP, cholesterol and PEG2000-C 16 Ceramide -molar ratio of 45:45:10) dissolved in tert-butanol with nucleic acids dissolved in sucrose followed by freeze-drying and rehydration results in lipid particles that are isotonic and ready for direct in vivo injection. Particles are ~190nm in size with a polydispersity index of 0.32 and an overall charge of 45mV. The encapsulated siRNA was protected from serum 10 and show excellent pharmacokinetics with T 1/2 λz>40 h compared to other systems such as galactosylated cationic liposomes (T 1/2 λz>1h) 16 , PEGylated polyplexes (T 1/2 λz>1.5 h) 17 , or SNALPS (T 1/2 λz>6.5 h) 18 . This represented an advance in lipid formulation of siRNA for in vivo use.
As mentioned above, liposomes are prepared fresh for in vivo use as they aggregate, fuse or hydrolyse in aqueous solutions over time. As the HFDM method results in a dried matrix we postulated that these resulting lipoplexes would be highly stable over time. Indeed, our initial studies examined the longevity of the freeze-dried siRNA/lipid matrix stored at 4°C, or room temperature, for 4 weeks and showed that silencing was still significant at this time 10 . Here, we have extended these studies out to 12 months and looked at a range of different storage conditions. We examined the physical characteristics of the particles and their ability to silence target genes in vitro at various time points. Our data show that HFDM lipoplexes are highly stable and still active for in vitro silencing even 12 months post-production. Such post-production longevity has never previously been reported and represents a significant advance in the field.
MATERIALS AND METHODS

Cells and siRNA
HeLa cells were originally obtained from the American Type Culture Collection (ATCC) and were cultured as described previously 23 . The siRNA used in this study was Lamin A/C siRNA 24 obtained from Genesearch (Shanghai, China). siGlo red (Dharmacon, Lafayette, CO) was used as a qualitative transfection indicator as transfection efficiency.
Liposome formulations
Lipoplexes were prepared by Hydration of Freeze-Dried Matrix (HFDM) method as described previously 10 . Required amounts of DOTAP, cholesterol and PEG2000-C16Ceramide were dissolved in 1 mL of tert-butanol at a molar ratio of 45:45:10. 40 µg of siRNA was added to 1 mL of filtered sucrose solution before mixing with the lipid solution.
The resultant formulation was then snap-frozen and freeze-dried overnight (ALPHA 1-2 LDplus, Martin Christ, Germany) at a condensing temperature of −80°C and pressure of less than 0.1 mbar. Distilled H2O was then added to the lyophilised product with gentle shaking.
A Nitrogen/Phosphate (N/P) ratio of 4:1 was used for all formulations and three separate batches were made for each formulation condition (n=3). The final product contained 40 μ g siRNA in 300 μ L isotonic sucrose solution.
Particle Characterisation
Size, polydispersity and zeta potential of the resultant lipoplexes were measured using a Zetasizer Nano ZS™ (Malvern Instruments, Malvern, UK) following appropriate dilution in distilled water. Measurements were carried out at room temperature (RT), 4 o C and -20 o C with 10 runs per measurement undertaken. siRNA entrapment efficiency siRNA entrapment efficiencies were determined using the Quant-iT™ PicoGreen® reagent (Invitrogen) as previously described 10 .
Lipoplex cell uptake analysis
Cells were forward-transfected with 40μM of siGlo red. Cell uptake efficiency was assessed by flow cytometry 24h post-transfection on a BD LSR FORTESSA TM cell analyser (BD bioscience, San Jose, CA)
In vitro siRNA transfection
In vitro siRNA transfection of liposome-complexed siRNA was performed as previously described 10 . HeLa cells were seeded the day before the transfection experiment at a density of 75,000 cells per well in a 6 well plate. A final concentration of 40 nM liposome-entrapped siRNA suspended in primocin-free complete media was then added to each well. siRNAs were left on cells for 8 h, and cells were then incubated in primocin-containing media for 3 days at 37 o C. The level of gene knockdown was determined by qPCR analysis.
qPCR Extract of RNA, cDNA generation, and qPCR were carried out as described previously 23 .
Real time primers used: Lamin A/C forward 5'-TGGAGATGATCCCTTGCTGA-3', Lamin 
RESULTS AND DISCUSSION
We have previously showed that storage of our formulated lipoplexes for 1 month at room temperature (RT) and 4 o C did not affect its physiochemical properties 10 . However, the physiochemical stability of the lipoplexes have never been tested outside these storage conditions. The stability of dried-state lipoplexes was investigated up to 12 months postmanufacture. Following formulation, the particles were stored at either RT, 4 o C or -20 o C.
Compared to freshly-prepared lipoplexes, the particle size, zeta potential and polydispersity index (PDI) of the lipoplexes did not vary over time a teach storage condition (Figure 1 ).
Lipoplex powder stored at RT displayed greater variation in both size and PDI upon rehydration, likely due to varying humidity levels during storage ( Figure 1A , Figure 1B ).
More importantly, no variation in the surface charge (or zeta potential) of particles was observed when stored at any temperature over a 12-month period ( Figure 1C) , which is important for the stability of the particles and remaining free from agglutination when delivered into the bloodstream. In contrast to what we previously observed 10 To assess whether storage time and temperature have any effect on the functional capability of the lipoplexes, the gene knockdown ability of siRNA-loaded lipoplexes was tested in vitro.
In vitro cell uptake efficiency of lipoplexes stored over time at varying temperatures were comparable to that of freshly prepared lipoplexes (Figure 2A ). Liposome powders were rehydrated at each time point, complexed with siRNAs and applied to HeLa cells to determine knockdown of the non-essential structural protein, lamin A/C. qPCR analysis revealed over 50% decrease of lamin A/C mRNA expression in HeLa cells treated with A/Cspecific siRNA compared to untransfected cells, irrespective of the storage conditions ( Figure   2B ). The degree of gene knockdown was comparable to that of freshly prepared liposomes suggesting that storage time and temperature have minimal effect on the gene-silencing efficiency of the siRNAs-complexed with lipoplexes.
Previous studies have investigated the stability of dried-state liposomal preparations at different temperatures (i.e. 37 o C to 60 o C) over a 1-month period 19 , this is the first study to investigate the physiochemical and functional effects of the prolonged storage of lipoplexes over a longer period of time (i.e. 12 months) and at lower temperatures. We developed this lyophilization procedure to ensure effective long-term storage of our lipoplexes, even at room temperature, as lipoplex suspensions are known to be unstable in aqueous suspension for long-term storage, especially with respect to hydrolysis and size stability. To date no data on the long term (up to 12 months) viability of siRNA-loaded liposomes have, to our knowledge, been published. There are longevity studies investigating traditional liposomes loaded with plasmid DNA. For example, an early study of unextruded liposomes made from DMRIE:DOPE complexed with plasmid DNA showed that when frozen as a aqueous solution they retained activity when thawed 12 months later 20 . More recently it was showed that DC-Cholesterol: DOPE liposomes loaded with plasmid DNA and freeze-dried were stable following 3 months storage at RT and 40°C, although storage at 60°C resulted in lost DNA structure 21 . Others have investigated the stability of DNA oligonucleotide-loaded liposomes for antisense therapies, which changed size and lost ODN content over 12 months (RT) or 90 days (frozen) 22 . However, the functionality of these stored lipoplexes was not examined. Overall, we show that RT was inferior for storage, resulting in an increased particle size and polydispersity from 3 months onwards. Storage at 4°C and -20°C resulted in no changes in lipoplexes and silencing ability. Overall, HFDM liposomes exhibit excellent long-term storage characteristics. 
